Research & Development: Page 43
-
PharmaVoice Team/PharmaVoice
A Paradigm Shift Towards Better Healthcare for All
The world and technology are racing ahead of the clinical trials industry. Digital health technologies (DHTs) continue to advance while clinical research remains slow to embrace efficient technologies and offerings that are widely being deployed in healthcare. The result is a market where a new m...
By Isaac Rodriguez-Chavez • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Will Decentralized Trials Finally Drive Meaningful Drug Development? Transformation?
Our industry has come a long way since the early days of clinical research. However, as time goes on clinical trials are becoming more complex, and if these complexities aren’t well managed patients bear the burden. When patients sign up to participate in a clinical study, they’re placing tremend...
By Maria Fotiu • Feb. 1, 2021 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Commanders & Chiefs: Clinical Services C-Suite
CROs and other clinical services companies have positioned themselves to be valued partners to biopharma companies. The executives of these companies are charged with not only setting the strategic direction for their organization but setting the pace for innovation to make the clinical trial pro...
By PharmaVoice Team • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Upfront
DTRA Launches to Democratize and Accelerate Clinical Trials A new global industry coalition — Decentralized Trials & Research Alliance (DTRA) — aims to dramatically increase access for all patient populations in clinical trials and research. DTRA’s goal is to unite stakeholders, including hea...
By PharmaVoice Team • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
Upfront
#NoGoingBack Almost three dozen signatory companies collaborated to form the #NoGoingBack movement, which is committed to continuing the progress made in clinical research during the COVID-19 pandemic. According to the movement, the industry has learned bold new ways to conduct trials due to COVI...
By PharmaVoice Team • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
HealthTech
Tiny Robots Tumble Through Organs to Deliver Drugs Trend Watch: From patient rides to telehealth specialty visits, healthtech continues to forge new paths for better patient outcomes. Tiny Robots Walk Through Colon to Deliver Drugs, Sample Tissue A rectangular robot as tiny as a few human hairs c...
By PharmaVoice Team • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
2021 Year in Preview: The Year to Come and the Year That Was
Who knew? 2020 will be defined as one of the most tumultuous years in history: a global pandemic and civil strife giving way to innovation and greater collaboration. Even as COVID-19 vaccines make their way through safety trials and treatments receive expedited review and approval, the 2021 cryst...
By Taren Grom • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Technology Solutions: Disrupting Innovation with Digital Solutions
Healthcare is undergoing a massive transformation with increased emphasis on digital technologies in all areas. According to Deloitte research, biopharma companies recognize that digital transformation will aid product and service innovation, greater customer engagement, and improvements across R...
By PharmaVoice Team • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Virtual Trials: Navigating Change and Avoiding Blinds Spots
As 2020 draws to a close, we reflect on the changes we have had to make in all facets of our lives due to the pandemic. Some were overdue and some are here to stay. Some were easy to adopt and others we resisted. Change of any sort, positive or negative, is known to be one of life’s great stresso...
By Kenneth G. Faulkner • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Four Ways Predictive Analytics Can Strengthen Your Commercialization Efforts
Over the past few years, artificial intelligence (AI) and machine learning (ML) have been trending topics in healthcare but are now being propelled to the forefront of clinical decision support and care delivery. Some organizations, however, have been slow to adopt the utilization of predictive a...
By Steve Mack • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
A New Framework for Improving Brand Performance
Why Managing Brand Performance is So Challenging Brand performance appears to be a straightforward concept to understand. However, the reality is that within pharmaceutical organizations, each business function has its own perspective of how brand performance should be planned for, monitored, and...
By Pankaj Gupta • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Telehealth: Ready or Not — <del>Here it Comes</del>… It's Here to Stay
Our world is changing more rapidly than ever before, but certain constants remain imperative in the healthcare arena — human connection and access to education. Healthcare professionals (HCPs) need to be able to connect with their patients to properly assess their conditions. HCPs need access to ...
By Christine Molbury • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
The Next Chapter for Real World Evidence: Validating Data with the Patient Voice
In June 2020, in accordance with the 21st Century Cures Act of 2016 and the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) launched Project Patient Voice. This patient-focused drug development initiative facilitates systematic approaches to collecting and usin...
By Ramita Tandon • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
COVID-19: Silver Linings
COVID-19 has stretched our industry to adjust to all types of new “normals," yet amid all of the disruption and loss of life, there are pockets of light that are expected to lift the life sciences and its people to new heights. Of all the industries that have been impacted across the globe, the l...
By Taren Grom • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Expanding the Spectrum of Clinical Trials
In recent years, pharma and biotech companies have become more aware of the lack of representation of certain demographics in clinical trials and its resulting ramifications. Although the participation of women in clinical trials has improved in recent years, the participation of racial and ethni...
By Carolyn Gretton • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Centering on the Patient by Decentralizing Clinical Trials
When it comes to decentralizing clinical trials, what was long a cracked door has been flung open wide by the COVID-19 pandemic. With COVID-19 sparking major upheaval in clinical trial execution, sponsors, CROs, and other supporters of drug development have been forced to adopt tools long used in...
By Carolyn Gretton • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Health Consumerism on the Rise
COVID-19 has pushed the promise of healthcare consumerism into the open, creating a space where patients have a real voice in their healthcare decisions. The healthcare consumer of the future is arriving faster than anticipated, fueled by the COVID-19 pandemic. Health consumerism, which was begin...
By Robin Robinson • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Speak Out: Making Data Central to Your CNS and Pain Trials
A Therapeutic-Area-Specific Approach to Data Capture Solutions For data capture, CNS and pain trials are demanding, with complicated eligibility criteria, extensive monitoring requirements, comprehensive data collection, and substantial demands on patients. To design a great solution, we consulte...
By Kyle Hogan • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Upfront
Takeda’s Innovators in Science Award Takeda Pharmaceuticals and the New York Academy of Sciences are drawing attention to the urgent needs of patients worldwide affected by an estimated 7,000 rare diseases. The 2020 Innovators in Science Award recognizes scientists from around the globe for their...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
HealthTech
Organ-on-a-Chip Transforms Drug Development Trend Watch: Healthtech Applications Run the Gamut from Chip Technology to EHRs, to Electronic Skin and Clinical Trials Draper’s Ex Vivo Immuno-oncology Dynamic Environment for Tumor biopsies (EVIDENT) is a microfluidic platform that maintains tumor fra...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Case Study: Leveraging AI for Meaningful Clinical Trials
Clinical trial sponsors seeking to develop new drugs and therapies face unique challenges, particularly when it comes to understanding patient dosing and response to therapy. This aspect can be difficult, as patients often: Do not take their medicine regularly, or at all Take creative measures to...
By Rich Christie • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
AI and Drug Discovery
Discovering and bringing new drugs to market is notoriously slow and costly for a reason. Science moves slowly because of the incredibly complex nature of human biology and the difficulty of sluggish recruitment of clinical trials. And in spite of greater investments in R&D by pharmaceutical ...
By Claire Bonaci • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
The Accessibility of AI: Innovation at Your Fingertips
The availability of datasets keeps growing exponentially. With this we are witnessing an escalation of available new life-altering systems. Some of these tools are highly autonomous and can perform functions with little to no human intervention. Self-driving cars, rockets that land upright on dro...
By Max Divak • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Site Unseen? Virtual and Hybrid Trials the Way of the Future
Decentralized trials create new opportunities for reaching more patients and safeguarding them during a pandemic, but what do they mean for sites? The clinical trial landscape has been going through a period of rapid and profound change. Even before the COVID-19 pandemic, trial sites have faced m...
By Kim Ribbink • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Turning on the Switch Fulcrum’s proprietary product engine identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. Bringing more than 30 years of R&D experience to his role as president and CEO of Fulcrum Therapeutics, Robert Gould, Ph....
By Robert Gould • Sept. 1, 2020
Previous
